Skip to main navigation Skip to search Skip to main content

A cocktail of in vitro efficient phages is not a guarantee for in vivo therapeutic results against avian colibacillosis

Jessica Tsonos, Leon H. Oosterik, Huruma N. Tuntufye, Jochen Klumpp, Patrick Butaye, Henri De Greve, Jean-Pierre Hernalsteens, Rob Lavigne, Bruno M. Goddeeris

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

Abstract

Avian pathogenic Escherichia coli (APEC) causes colibacillosis in poultry, leading to important economic losses worldwide. To cure APEC-infected chickens, a cocktail of four different APEC-specific bacteriophages (phages) was composed and tested. Specific phages were selected from a collection of phages isolated in Belgium. The selection was based on their obligate lytic infection cycle, a broad host range, low cross-resistance and low frequency of development of resistant APEC mutants. Genome analysis of the phages indicated they were close relatives of T4 and N4, considered to be safe in vivo. Chickens were intratracheally infected with APEC strain CH2 (serogroup O78), causing a mortality of about 50% during the seven days following the infection. The phage cocktail was administered 2. h after the infection, via three different ways: intratracheally, intra-esophageally or via the drinking water. Treated groups did not show a significant decrease in mortality, lesion scores or weight loss compared to untreated groups, although the APEC-specific phages could be re-isolated from the lung and heart of chickens that were euthanized. Moreover, the re-isolated bacteria from infected chickens had remained sensitive to the phage cocktail. Our results indicate that the efficiency of the phage cocktail used in treating CH2-infected chickens in vivo is negligible, even though in vitro, the phages in the cocktail were able to efficiently lyse the APEC strain CH2. Our results emphasize that the 'traditional' pathway of isolation, followed by phenotypical and genotypical characterization of phages composing the cocktail, does not lead to success in phage therapy in all cases. © 2013 Elsevier B.V.
Original languageEnglish
Pages (from-to)470-479
JournalVeterinary Microbiology
Volume171
Issue number3-4
DOIs
Publication statusPublished - 16 Jul 2014
Externally publishedYes

Bibliographical note

Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

Funding

This study was funded by the Belgian Federal Public Service of Health, Food Chain Safety and Environment (www.health.belgium.be/; contract RT 09/8 APECON) and by CODA-CERVA (www.coda-cerva.be; contract APEC-BED). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Keywords

  • Avian pathogenic Escherichia coli
  • Bacteriophage therapy
  • Colibacillosis

Fingerprint

Dive into the research topics of 'A cocktail of in vitro efficient phages is not a guarantee for in vivo therapeutic results against avian colibacillosis'. Together they form a unique fingerprint.

Cite this